The company's expenses declined as a share of revenue. Compute costs, its largest cost, fell from more than 250% of revenue to 48%.

The innovative medicine business posted 7.9% operational growth. TREMFYA generated $2.4 billion in quarterly sales. Those sales offset STELARA's decline.

Why CoStar stock sank 14% after earnings: revenue miss, Vexcel acquisition, and key metrics investors should watch now.

Celestica's earnings per share rose 109%, beating expectations. The company expects free cash flow to be negative in 2027. The rating on the shares remains Hold.

Celestica delivered Q3 results that exceeded estimates, with revenue up 83% YoY and EPS rising 109%. I rate CLS stock as Strong Buy. Click to read my full update.

Revenue beat both market expectations and optimistic forecasts. The result eased concerns about slowing demand.

Discover why Space Exploration Technologies, aka SpaceX, was upgraded to Buy after Flight 14, EPS reversal, and Starship scaling. Click for this SPCX stock update.

Gross margin guidance rose to 12%-12.5%, implying gross profit of about $2.33 billion. That compares with $1.59 billion previously.

Robinhood posted record net deposits of $21.7 billion. ARPU rose 24% year over year. Each of its 13 business lines now generates more than $100 million in annual revenue.